MacroGenics received orphan drug designation from the FDA for its investigational gastric cancer drug margetuximab.
An early trial of AstraZeneca’s MET inhibitor savolitinib in gastric cancer revealed mutations that confer drug resistance.
A review of clinical trials reveals that acupuncture and acupressure help reduce pain and opioid usage in cancer patients.
The new targeted drug Enhertu showed a promising response rate in a trial of patients with HER2-positive gastric cancer.
Two patients with gastroesophageal cancer responded well to Gritstone Oncology’s immune-stimulating treatment in an early trial.